Drugs that contain Lamivudine; Raltegravir Potassium

1. Drug name - DUTREBIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7820660 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(6 months from now)

US7169780 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2023

(a year from now)

US7754731 MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Mar, 2029

(6 years from now)

CN102219750A MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitor Relative To Hiv Integrase
Oct, 2022

(18 days from now)

CN1700918A MERCK SHARP DOHME N About The Hiv Integrase-Substituted Hydroxy Pyrimidinone Carboxamide Inhibitors
Oct, 2022

(18 days from now)

CN102229605B MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitor Relative To Hiv Integrase
Oct, 2022

(18 days from now)

CN102229605A MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitor Relative To Hiv Integrase
Oct, 2022

(18 days from now)

CN1700918B MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitor Relative To Hiv Integrase
Oct, 2022

(18 days from now)

CN102219750B MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Oct, 2022

(18 days from now)

CN101068793B MERCK SHARP DOHME Potassium Salt Of An Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

CN101068793A MERCK SHARP DOHME Sylvine Of Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

IN200400868P4 MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Oct, 2022

(18 days from now)

IN212400B MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Oct, 2022

(18 days from now)

EP1441735B1 MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Jan, 2023

(2 months from now)

EP1441735A1 MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Jan, 2023

(2 months from now)

EP1819700B1 MERCK SHARP DOHME Potassium Salt Of An Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

EP1819700A2 MERCK SHARP DOHME Potassium Salt Of An Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

EP1819683B1 MERCK SHARP DOHME Potassium Salt Of An Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

EP1819683A2 MERCK SHARP DOHME Potassium Salt Of An Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7217713 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct, 2022

(18 days from now)

US7435734 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct, 2022

(18 days from now)

US7217713

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr, 2023

(6 months from now)

US7435734

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr, 2023

(6 months from now)

US7169780

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr, 2024

(1 year, 6 months from now)

US7754731

(Pediatric)

MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor Sep, 2029

(6 years from now)

Treatment: Treatment of hiv-1 infection

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG;EQ 300MG BASE TABLET;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.